ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) (clinicaltrials.gov) - Sep 24, 2026 - P1 | N=120 | Active, not recruiting | Sponsor: USWM CT, LLC | Trial primary completion date: Dec 2026 ➔ Apr 2026
Monotherapy • Trial primary completion date • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Genito-urinary Cancer • Head and Neck Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Urothelial Cancer • MAGEA4
|